MA32838B1 - Procede de modulation de l'activite antagoniste d'un anticorps monoclonal - Google Patents

Procede de modulation de l'activite antagoniste d'un anticorps monoclonal

Info

Publication number
MA32838B1
MA32838B1 MA33899A MA33899A MA32838B1 MA 32838 B1 MA32838 B1 MA 32838B1 MA 33899 A MA33899 A MA 33899A MA 33899 A MA33899 A MA 33899A MA 32838 B1 MA32838 B1 MA 32838B1
Authority
MA
Morocco
Prior art keywords
antibody
antibody activity
modifying
monoclonal antibodies
target molecule
Prior art date
Application number
MA33899A
Other languages
Arabic (ar)
English (en)
Inventor
Liliane Goetsch
Thierry Wurch
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2008/055664 external-priority patent/WO2010064090A1/fr
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA32838B1 publication Critical patent/MA32838B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

L'invention a trait au domaine de l'ingénierie des anticorps et plus particulièrement à un procédé de criblage d'anticorps et/ou de modulation de l'activité agoniste ou antagoniste d'anticorps, et plus particulièrement encore à un procédé améliorant l'activité antagoniste d'un anticorps monoclonal dirigé contre une molécule cible spécifique ou contre l'un de ses fragments fonctionnels divalents ou l'un de ses dérivés, ledit anticorps étant capable d'inhiber une ou plusieurs des activités biologiques de ladite molécule cible, et ledit procédé comportant une étape de reconfiguration de la région charnière, consistant à modifier la séquence d'acides aminés de ladite région par suppression, addition ou substitution d'au moins un acide aminé. L'invention porte également sur des polypeptides utilisables dans ladite méthode de modulation, et sur les anticorps ainsi obtenus.
MA33899A 2008-12-02 2011-05-31 Procede de modulation de l'activite antagoniste d'un anticorps monoclonal MA32838B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB2008/055664 WO2010064090A1 (fr) 2008-12-02 2008-12-02 Procédé de modulation de l'activité antagoniste d'un anticorps monoclonal
US18440609P 2009-06-05 2009-06-05
PCT/EP2009/066205 WO2010063746A1 (fr) 2008-12-02 2009-12-02 Procédé de modulation de l'activité antagoniste d'un anticorps monoclonal

Publications (1)

Publication Number Publication Date
MA32838B1 true MA32838B1 (fr) 2011-11-01

Family

ID=41668304

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33899A MA32838B1 (fr) 2008-12-02 2011-05-31 Procede de modulation de l'activite antagoniste d'un anticorps monoclonal

Country Status (22)

Country Link
US (3) US9676839B2 (fr)
EP (2) EP2370464B1 (fr)
JP (1) JP5832899B2 (fr)
KR (2) KR20110091519A (fr)
CN (2) CN105820241A (fr)
AR (1) AR074438A1 (fr)
AU (1) AU2009324145B2 (fr)
BR (1) BRPI0923228B1 (fr)
CA (1) CA2744065C (fr)
DK (1) DK2370464T3 (fr)
ES (1) ES2600254T3 (fr)
GE (1) GEP20135931B (fr)
HK (1) HK1163704A1 (fr)
IL (1) IL213272A (fr)
MA (1) MA32838B1 (fr)
MX (1) MX2011005569A (fr)
NZ (1) NZ592830A (fr)
SA (1) SA109300723B1 (fr)
TN (1) TN2011000253A1 (fr)
TW (1) TWI631341B (fr)
WO (1) WO2010063746A1 (fr)
ZA (1) ZA201103831B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006106905A1 (fr) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Procede pour la production de polypeptide au moyen de la regulation d’un ensemble
ES2568436T3 (es) 2006-03-31 2016-04-29 Chugai Seiyaku Kabushiki Kaisha Procedimiento para controlar la farmacocinética en sangre de anticuerpos
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
SG10201605394SA (en) 2007-09-26 2016-08-30 Chugai Pharmaceutical Co Ltd Modified Antibody Constant Region
EP3689912A1 (fr) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Procédé de modification d'un anticorps par point isoélectrique par substitution d'acide aminé dans cdr
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
EP2481752B1 (fr) 2009-09-24 2016-11-09 Chugai Seiyaku Kabushiki Kaisha Régions constantes modifiées d'un anticorps
JP5889181B2 (ja) 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
AU2011226103C1 (en) 2010-03-10 2016-04-28 Genmab A/S Monoclonal antibodies against c-Met
US9931400B2 (en) 2012-09-12 2018-04-03 Samsung Electronics Co., Ltd. Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
KR102441231B1 (ko) 2013-09-27 2022-09-06 추가이 세이야쿠 가부시키가이샤 폴리펩티드 이종 다량체의 제조방법
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
CN107172880B (zh) * 2014-03-24 2021-09-28 癌症研究技术有限公司 含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途
EP3699198A1 (fr) 2014-11-17 2020-08-26 Regeneron Pharmaceuticals, Inc. Procédés pour le traitement de tumeurs à l'aide d'anticorps bispécifiques cd3xcd20
JP6773679B2 (ja) 2015-03-30 2020-10-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｆｃガンマ受容体に対する結合が低下した重鎖定常領域
EP3279216A4 (fr) 2015-04-01 2019-06-19 Chugai Seiyaku Kabushiki Kaisha Procédé pour la production d'un hétéro-oligomère polypeptidique
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
WO2018081448A1 (fr) * 2016-10-26 2018-05-03 The Board Of Trustees Of The Leland Stanford Junior University Régions charnières d'immunoglobuline modifiées pour réduire l'hémagglutination
JP2021535142A (ja) 2018-08-31 2021-12-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. Ｃｄ３／ｃ２０二重特異性抗体のサイトカイン放出症候群を軽減する投与戦略

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0315457D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
AU2004309275B2 (en) 2003-12-25 2010-12-23 Kyowa Kirin Co., Ltd. Mutants of anti-CD40 antibody
US8008443B2 (en) * 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
JP5142998B2 (ja) * 2005-07-18 2013-02-13 アムジエン・インコーポレーテツド ヒト抗ｂ７ｒｐ１中和抗体
US8652469B2 (en) * 2005-07-28 2014-02-18 Novartis Ag M-CSF-specific monoclonal antibody and uses thereof
KR20090013763A (ko) * 2006-03-23 2009-02-05 기린 파마 가부시끼가이샤 인간 트롬보포이에틴 수용체에 대한 아고니스트 항체
EP2004693B1 (fr) * 2006-03-30 2012-06-06 Novartis AG Compositions et procedes d'utilisation associes a des anticorps de c-met
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody

Also Published As

Publication number Publication date
US20150239958A1 (en) 2015-08-27
ZA201103831B (en) 2012-01-25
AU2009324145A1 (en) 2010-06-10
BRPI0923228A2 (pt) 2021-02-09
EP3048113A1 (fr) 2016-07-27
DK2370464T3 (en) 2016-11-21
AR074438A1 (es) 2011-01-19
US20130109839A1 (en) 2013-05-02
AU2009324145B2 (en) 2015-01-22
US20110263830A1 (en) 2011-10-27
CN102232086B (zh) 2016-03-16
EP2370464B1 (fr) 2016-07-27
IL213272A0 (en) 2011-07-31
ES2600254T3 (es) 2017-02-08
IL213272A (en) 2017-08-31
BRPI0923228B1 (pt) 2022-03-03
KR20110091519A (ko) 2011-08-11
TW201024734A (en) 2010-07-01
CN105820241A (zh) 2016-08-03
CN102232086A (zh) 2011-11-02
TN2011000253A1 (en) 2012-12-17
KR20170021378A (ko) 2017-02-27
WO2010063746A1 (fr) 2010-06-10
GEP20135931B (en) 2013-10-10
SA109300723B1 (ar) 2014-10-27
CA2744065A1 (fr) 2010-06-10
US9676839B2 (en) 2017-06-13
TWI631341B (zh) 2018-08-01
NZ592830A (en) 2013-03-28
CA2744065C (fr) 2017-09-12
JP2012510281A (ja) 2012-05-10
RU2011124749A (ru) 2013-01-10
JP5832899B2 (ja) 2015-12-16
KR101971806B1 (ko) 2019-08-27
EP2370464A1 (fr) 2011-10-05
MX2011005569A (es) 2011-06-16
HK1163704A1 (zh) 2012-09-14

Similar Documents

Publication Publication Date Title
MA32838B1 (fr) Procede de modulation de l'activite antagoniste d'un anticorps monoclonal
WO2010091182A3 (fr) Procédés pour cribler des agents candidats pour la modulation de la prorénine et de la rénine, tests de détection de la prorénine, et anticorps qu'ils emploient
MY157173A (en) Modified humanised anti-interleukin-18
EA201070695A1 (ru) Молекулы гуманизированных антител, специфичных к il-31
EA201992670A1 (ru) Способ получения биспецифических антител, биспецифические антитела и терапевтическое применение таких антител
ATE530195T1 (de) Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür
CR20120587A (es) Moléculas de unión al antígeno que fijan egfr, vectores que las codifican y uso de las mismas
EA200801621A1 (ru) Антитела, направленные на her-3, и их применение
MX2009008608A (es) Anticuerpos monoclonales anti-cxcl13.
BRPI0613382A8 (pt) anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor
RS54113B1 (en) COMPOSITIONS AND PROCEDURES FOR ANTIBODIES ON THE C5 COMPLEMENTARY PROTEIN
DE602006013029D1 (de) Anti-egfr-antikörper
MX2018008680A (es) Moleculas de union especifica a proteina de union a adn de respuesta transactiva de 43 kda (tdp-43).
EA201001762A1 (ru) Антитела и способы их получения
EA201592042A1 (ru) Композиции антител против cgrp и их применение
MX2018013008A (es) Anticuerpos st-2 humanos solubles y ensayos.
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
TR201910348T4 (tr) Matriks metalloproteinaz 9 için antikorlar.
DK1869085T3 (da) Hidtil ukendt anti-PLGF-antistof
DE602005022830D1 (de) Weniger immunogene bindungsmoleküle
ATE493439T1 (de) Monoklonale ykl-40-antikörper
WO2009088924A3 (fr) Procédés et matériaux pour une amélioration d'affinité ciblée
NO20090069L (no) Malrettede forbindelser rettet mot binding til PDGFR-alfa og deres anvendelse
NZ594682A (en) Fully human antibodies specific to cadm1
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper